Trial · NCT04593823
Results by group122
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 122
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Win Ratio of Composite Endpoint | Furoscix Infusor | 228 | Number of Wins for the group | ||
| Win Ratio of Composite Endpoint | Continued Medical Therapy | 206 | Number of Wins for the group | ||
| Number of Cardiovascular Deaths | Furoscix Infusor | No | 33 | Participants | |
| Number of Cardiovascular Deaths | Continued Medical Therapy | No | 17 | Participants | |
| Number of Cardiovascular Deaths | Furoscix Infusor | Yes | 1 | Participants | |
| Number of Cardiovascular Deaths | Continued Medical Therapy | Yes | 0 | Participants | |
| Number of Heart Failure Hospitalizations | Furoscix Infusor | No | 29 | Participants | |
| Number of Heart Failure Hospitalizations | Continued Medical Therapy | No | 13 | Participants | |
| Number of Heart Failure Hospitalizations | Furoscix Infusor | Yes | 5 | Participants | |
| Number of Heart Failure Hospitalizations | Continued Medical Therapy | Yes | 4 | Participants | |
| Number of Urgent ED/Clinic Visits for Worsening Heart Failure | Furoscix Infusor | No | 34 | Participants | |
| Number of Urgent ED/Clinic Visits for Worsening Heart Failure | Continued Medical Therapy | No | 17 | Participants | |
| Number of Urgent ED/Clinic Visits for Worsening Heart Failure | Furoscix Infusor | Yes | 0 | Participants | |
| Number of Urgent ED/Clinic Visits for Worsening Heart Failure | Continued Medical Therapy | Yes | 0 | Participants | |
| NT-proBNP Change From Baseline | Furoscix Infusor | -7.195 | Full Range -55.27 to 379.58 | percentage change from baseline (pg/mL) | |
| NT-proBNP Change From Baseline | Continued Medical Therapy | -2.170 | Full Range -53.37 to 36.08 | percentage change from baseline (pg/mL) | |
| Number of Heart Failure Event Free Survival Days | Furoscix Infusor | 23.2 | Standard Deviation 4.79 | days | |
| Number of Heart Failure Event Free Survival Days | Continued Medical Therapy | 14.3 | Standard Deviation 10.14 | days | |
| Number of Subjects Deceased or HF Event Occurred | Furoscix Infusor | No | 28 | Participants | |
| Number of Subjects Deceased or HF Event Occurred | Continued Medical Therapy | No | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04593823/results